Horn & Co. regularly advises Israeli and international clients on their full range of corporate finance transactions. Horn & Co. has special experience in registration and issuance of securities of technology companies on US and Israeli securities exchanges. Recent examples include:
o The incorporation of incubator companies, supported by funding from the Office of the Chief Scientist;
o Preliminary funding by founders, and their friends and family;
o Seed rounds by angels and external investors;
o Venture capital backed funding rounds;
o Strategic investments by multinational companies;
o Registration and issuance of securities on US and Israeli securities exchanges, including IPOs, follow on offerings and PIPEs, (since October 2014 - the initial public offering and follow on offerings of Vascular Biogenics Ltd. (Nasdaq: VBLT, and several PIPE transactions and public follow on offerings of Collplant Holdings Ltd. (TASE) and Therapix Bio Ltd. (TASE)) ;
o Representation of Israeli and US financial institutions in structured finance transactions, and advice on ISDA regulations.
Horn & Co. has special experience in registration and issuance of securities of technology companies on US and Israeli securities exchanges, including IPOs, follow-on offerings and PIPEs. We also advise board members and management of Tel Aviv Stock Exchange-traded technology companies with respect to corporate governance, ongoing activities, reporting requirements and restrictions imposed by law and regulation. During 2010, we were involved in many of the major public financing transactions of biotechnology companies. Examples of transactions on the Tel Aviv Stock Exchange include:
o Accompanying a Delaware Company traded on the Tel Aviv Stock Exchange in submission of a shelf prospectus on TASE, and a parallel submission of Form S-1 to the SEC. Previous submission of a Form S-1 for the purpose of registering the company’s securities, and assuring that the company’s securities in Israel shall be tradable. Representation of the company – as well as the board – in a potential conflict with a controlling shareholder, and in the amicable resolution of the conflict. Representation of the Company in 2 PIPE transactions in 2010.
o Representation of a software development company in submission of a shelf prospectus to the TASE, as well as the consummation of a PIPE transaction.
o Representation of CollPlant Ltd. in its merger with Portfolio Green Ltd. (today – CollPlant Holdings Ltd.), including: drafting of an information statement, negotiating the transaction, participation in the drafting of the prospectus and obtaining requisite regulatory and corporate approvals.
o Ongoing representation of ATI (Ashkelon Technology Incubator), which has merged with Gefen Investments Biomed Ltd. The ongoing involvement in such transactions includes the submission of reports to and direct communication with the TASE and the Israel Securities Authority, and ongoing advice to the boards of directors and committees of the traded companies.